Recurrent longitudinal myelitis as primary manifestation of SLE.
Lehnhardt
F-G
FG
Impekoven
P
P
Rubbert
A
A
Burghaus
L
L
Neveling
M
M
Heiss
W-D
WD
Jacobs
A H
AH
D000328:Adult; D016736:Antiphospholipid Syndrome / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008279:Magnetic Resonance Imaging; D008775:Methylprednisolone / Q000627:therapeutic use; D009187:Myelitis / Q000209:etiology* / Q000473:pathology; D012008:Recurrence; D012074:Remission Induction
D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D008775:Methylprednisolone